Dr MedSc - Phio Pharmaceuticals Interim Director
| PHIO Stock | USD 1.47 0.10 6.37% |
Insider
Dr MedSc is Interim Director of Phio Pharmaceuticals Corp
| Age | 68 |
| Phone | 508 767 3861 |
| Web | https://phiopharma.com |
Phio Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.6107) % which means that it has lost $0.6107 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2686) %, meaning that it created substantial loss on money invested by shareholders. Phio Pharmaceuticals' management efficiency ratios could be used to measure how well Phio Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| RPh PharmD | Elevation Oncology | 40 | |
| Valerie MD | Elevation Oncology | 47 | |
| Joseph Ferra | Elevation Oncology | 50 | |
| LaBella MS | ZyVersa Therapeutics | 66 | |
| Pablo MD | ZyVersa Therapeutics | N/A | |
| Timur Dogan | Cardio Diagnostics Holdings | 36 | |
| John Cini | Sonnet Biotherapeutics Holdings | 73 | |
| Gabriel BA | Immix Biopharma | 38 | |
| Manuel Dafonseca | Sonnet Biotherapeutics Holdings | N/A | |
| Jason Assad | 180 Life Sciences | N/A | |
| Karen Cashmere | ZyVersa Therapeutics | 73 | |
| Meeshanthini Dogan | Cardio Diagnostics Holdings | 36 | |
| Jonathan Rothbard | 180 Life Sciences | 71 | |
| David Dornan | Elevation Oncology | 47 | |
| Raphael Mechoulam | 180 Life Sciences | N/A | |
| MBA MD | Immix Biopharma | 49 | |
| JD MBA | Immix Biopharma | N/A | |
| DSc MSE | Immix Biopharma | 75 | |
| Waldemar Priebe | Cns Pharmaceuticals | N/A | |
| Brian Sullivan | Elevation Oncology | N/A | |
| MD FACP | Sonnet Biotherapeutics Holdings | 67 | |
Management Performance
| Return On Equity | -1.27 | ||||
| Return On Asset | -0.61 |
Phio Pharmaceuticals Corp Leadership Team
Elected by the shareholders, the Phio Pharmaceuticals' board of directors comprises two types of representatives: Phio Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Phio. The board's role is to monitor Phio Pharmaceuticals' management team and ensure that shareholders' interests are well served. Phio Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Phio Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert Bitterman, Independence Chairman of the Board | ||
| Esq CPA, CFO Officer | ||
| Dr MedSc, Interim Director | ||
| Linda Mahoney, Senior Development | ||
| Jim Cardia, VP Operations | ||
| Caitlin Kontulis, VP Secretary |
Phio Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Phio Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.27 | ||||
| Return On Asset | -0.61 | ||||
| Current Valuation | (477.66 K) | ||||
| Shares Outstanding | 860.72 K | ||||
| Shares Owned By Insiders | 5.89 % | ||||
| Shares Owned By Institutions | 2.07 % | ||||
| Number Of Shares Shorted | 99.59 K | ||||
| Price To Earning | (0.80) X | ||||
| Price To Book | 1.61 X | ||||
| Price To Sales | 48.01 X |
Pair Trading with Phio Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Phio Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Phio Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Phio Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Phio Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Phio Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Phio Pharmaceuticals Corp to buy it.
The correlation of Phio Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Phio Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Phio Pharmaceuticals Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Phio Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Phio Pharmaceuticals Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Phio Pharmaceuticals. If investors know Phio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Phio Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Phio Pharmaceuticals Corp is measured differently than its book value, which is the value of Phio that is recorded on the company's balance sheet. Investors also form their own opinion of Phio Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Phio Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Phio Pharmaceuticals' market value can be influenced by many factors that don't directly affect Phio Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Phio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Phio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Phio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.